154 related articles for article (PubMed ID: 30242253)
1. Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.
de Jong Y; Monderer D; Brandinelli E; Monchanin M; van den Akker BE; van Oosterwijk JG; Blay JY; Dutour A; Bovée JVMG
Oncogenesis; 2018 Sep; 7(9):74. PubMed ID: 30242253
[TBL] [Abstract][Full Text] [Related]
2. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
de Jong Y; van Maldegem AM; Marino-Enriquez A; de Jong D; Suijker J; Briaire-de Bruijn IH; Kruisselbrink AB; Cleton-Jansen AM; Szuhai K; Gelderblom H; Fletcher JA; Bovée JV
Lab Invest; 2016 Oct; 96(10):1128-37. PubMed ID: 27617402
[TBL] [Abstract][Full Text] [Related]
4. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
van Oosterwijk JG; Meijer D; van Ruler MA; van den Akker BE; Oosting J; Krenács T; Picci P; Flanagan AM; Liegl-Atzwanger B; Leithner A; Athanasou N; Daugaard S; Hogendoorn PC; Bovée JV
Am J Pathol; 2013 Apr; 182(4):1347-56. PubMed ID: 23415961
[TBL] [Abstract][Full Text] [Related]
5. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines.
Abdul Rahman SF; Muniandy K; Soo YK; Tiew EYH; Tan KX; Bates TE; Mohana-Kumaran N
Biochem Biophys Rep; 2020 Jul; 22():100756. PubMed ID: 32346617
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of hypoxia-inducible factor-1α are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma.
Chen C; Zhou H; Wei F; Jiang L; Liu X; Liu Z; Ma Q
J Orthop Res; 2011 Jan; 29(1):143-51. PubMed ID: 20661931
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
[TBL] [Abstract][Full Text] [Related]
9. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells.
Kim DW; Seo SW; Cho SK; Chang SS; Lee HW; Lee SE; Block JA; Hei TK; Lee FY
J Orthop Res; 2007 Jun; 25(6):820-8. PubMed ID: 17343283
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Huang K; Chen J; Yang MS; Tang YJ; Pan F
Cancer Biomark; 2017; 18(3):231-239. PubMed ID: 28085008
[TBL] [Abstract][Full Text] [Related]
13. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
15. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
[TBL] [Abstract][Full Text] [Related]
16. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
17. Selection of Effective Therapies Using Three-Dimensional
Palubeckaitė I; Venneker S; Briaire-de Bruijn IH; van den Akker BE; Krol AD; Gelderblom H; Bovée JVMG
Front Mol Biosci; 2020; 7():566291. PubMed ID: 33425984
[No Abstract] [Full Text] [Related]
18. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
19. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.
Dole MG; Jasty R; Cooper MJ; Thompson CB; Nuñez G; Castle VP
Cancer Res; 1995 Jun; 55(12):2576-82. PubMed ID: 7780971
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
